{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-060806","form_type":"8-K","ticker":"AKTX","cik":"0001541157","company_name":"Akari Therapeutics Plc","filed_at":"2024-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.905865+00:00","generated_at":"2026-06-01T21:01:49.390810+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Akari Therapeutics Q1 net loss $5.6M; cash $1.3M; merges with Peak Bio, cuts 67% workforce","bullets":["Q1 net loss $5.6M vs net income $1.0M in Q1 2023; adjusted net loss $6.2M excluding warrant gains.","Cash $1.3M as of March 31, 2024; issued $1M in unsecured convertible notes from CEO and Chairman.","Entered all-stock merger with Peak Bio, expected close Q3 2024; combined company will trade as AKTX.","Appointed Samir R. Patel as interim CEO; suspended HSCT-TMA program.","Reduced workforce by ~67% as part of restructuring to cut costs."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-060806","json":"https://secwatch.observer/filing/0000950170-24-060806.json","markdown":"https://secwatch.observer/filing/0000950170-24-060806.md","text":"https://secwatch.observer/filing/0000950170-24-060806.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024060806/0000950170-24-060806-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024060806/aktx-20240516.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T21:01:49.390810+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4aa9d4b6acd52501dfe506c62214f45ab595a863","claim":"Akari Therapeutics Plc reported the first quarter ended March 31, 2024 results: net income Net loss was approximately $5.6 million.","evidence_excerpt":"Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, has reported financial results for the first quarter ended March 31, 2024 as well as recent company highlights.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024060806/0000950170-24-060806-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Net income","value":"Net loss was approximately $5.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}